127 related articles for article (PubMed ID: 36250888)
21. Unlocking the potential of microfluidics in mass spectrometry-based immunopeptidomics for tumor antigen discovery.
Stutzmann C; Peng J; Wu Z; Savoie C; Sirois I; Thibault P; Wheeler AR; Caron E
Cell Rep Methods; 2023 Jun; 3(6):100511. PubMed ID: 37426761
[TBL] [Abstract][Full Text] [Related]
22. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract][Full Text] [Related]
23. Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical.
Kong Y; Jiang C; Wei G; Sun K; Wang R; Qiu T
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375228
[TBL] [Abstract][Full Text] [Related]
24. Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS.
Yin G; Huang J; Petela J; Jiang H; Zhang Y; Gong S; Wu J; Liu B; Shi J; Gao Y
Signal Transduct Target Ther; 2023 May; 8(1):212. PubMed ID: 37221195
[TBL] [Abstract][Full Text] [Related]
25. Correction: Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy.
Cancer Discov; 2023 Apr; 13(4):1026. PubMed ID: 37009704
[No Abstract] [Full Text] [Related]
26. Targeting the 'Undruggable' Driver Protein, KRAS, in Epithelial Cancers: Current Perspective.
Lam KK; Wong SH; Cheah PY
Cells; 2023 Feb; 12(4):. PubMed ID: 36831298
[TBL] [Abstract][Full Text] [Related]
27. Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy.
Song X; Zhou Z; Kang R; Tang D
Oncoimmunology; 2022; 11(1):2141978. PubMed ID: 36338145
[TBL] [Abstract][Full Text] [Related]
28. Immunogenic peptide discovery in cancer genomes.
Snyder A; Chan TA
Curr Opin Genet Dev; 2015 Feb; 30():7-16. PubMed ID: 25588790
[TBL] [Abstract][Full Text] [Related]
29. Creating MHC-Restricted Neoantigens with Covalent Inhibitors That Can Be Targeted by Immune Therapy.
Hattori T; Maso L; Araki KY; Koide A; Hayman J; Akkapeddi P; Bang I; Neel BG; Koide S
Cancer Discov; 2023 Jan; 13(1):132-145. PubMed ID: 36250888
[TBL] [Abstract][Full Text] [Related]
30. Molecular basis for antibody recognition of multiple drug-peptide/MHC complexes.
Maso L; Rajak E; Bang I; Koide A; Hattori T; Neel BG; Koide S
Proc Natl Acad Sci U S A; 2024 May; 121(22):e2319029121. PubMed ID: 38781214
[TBL] [Abstract][Full Text] [Related]
31. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
32. Recognition of xeno-(HLA, SLA) major histocompatibility complex antigens by mouse cytotoxic T cells is not H-2 restricted: a study with transgenic mice.
Kievits F; Wijffels J; Lokhorst W; Ivanyi P
Proc Natl Acad Sci U S A; 1989 Jan; 86(2):617-20. PubMed ID: 2783490
[TBL] [Abstract][Full Text] [Related]
33. Convergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers.
Cox AD; Ting JP; Der CJ
Cancer Discov; 2023 Jan; 13(1):19-22. PubMed ID: 36620884
[TBL] [Abstract][Full Text] [Related]
34. A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy.
Zhang Z; Rohweder PJ; Ongpipattanakul C; Basu K; Bohn MF; Dugan EJ; Steri V; Hann B; Shokat KM; Craik CS
Cancer Cell; 2022 Sep; 40(9):1060-1069.e7. PubMed ID: 36099883
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
